A Randomized, Placebo-controlled, Parallel Panel Study to Assess the Effects of REGN3500, Dupilumab, and Combination of REGN3500 Plus Dupilumab on Markers of Inflammation After Bronchial Allergen Challenge in Patients With Allergic Asthma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2019
Price : $35 *
At a glance
- Drugs Dupilumab (Primary) ; SAR 440340 (Primary) ; Fluticasone propionate
- Indications Allergic asthma
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 17 Jul 2019 Planned End Date changed from 29 Jan 2020 to 9 Dec 2019.
- 17 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated